World's Best Scientists 2026 revealed!
Aurélien Marabelle

Aurélien Marabelle

D-Index & Metrics

Immunology

D-Index
88
Citations
38224
World Ranking
1144
National Ranking
40

Medicine

D-Index
89
Citations
38467
World Ranking
12490
National Ranking
387

Aurélien Marabelle publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Aurélien Marabelle sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 486 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Aurélien Marabelle D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Aurélien Marabelle sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 88 D-Index — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Aurélien Marabelle is affiliated with the Institut Gustave Roussy in France. Their research primarily focuses on oncology and immunology within the medical field.

The scientist's recent publications include:

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, 2020, The Lancet Oncology
  • Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19, 2020, Cell
  • Cancer vaccines: the next immunotherapy frontier, 2022, Nature Cancer
  • Mechanisms and therapeutic implications of hypermutation in gliomas, 2020, Nature
  • Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression, 2021, Nature Cancer

Their frequent co-authors include:

  • Stéphane Champiat
  • Capucine Baldini
  • Jean-Marie Michot
  • Christophe Massard
  • François-Xavier Danlos

Marabelle's publications appear mostly in venues such as:

  • Annals of Oncology
  • European Journal of Cancer
  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research

The main field of study is Medicine, with a focus on several subfields including:

  • Oncology
  • Immunology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Pathology and Forensic Medicine

The scientist's main research topics encompass:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Immune Cell Function and Interaction
  • Genetic factors in colorectal cancer
  • Colorectal Cancer Treatments and Studies

Best Publications

  • Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

    Aurelien Marabelle;Dung T. Le;Paolo A. Ascierto;Anna Maria Di Giacomo

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Immune-related adverse events with immune checkpoint blockade: a comprehensive review

    J.M. Michot;C. Bigenwald;S. Champiat;M. Collins

  • Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

    J.M. Pitt;A. Marabelle;A. Marabelle;A. Eggermont;J.-C. Soria

  • Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

    Stephane Champiat;Stephane Champiat;Laurent Dercle;Samy Ammari;Christophe Massard

  • A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

    Roger Sun;Roger Sun;Elaine Johanna Limkin;Elaine Johanna Limkin;Maria Vakalopoulou;Maria Vakalopoulou;Laurent Dercle;Laurent Dercle

  • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

    Celine Boutros;Ahmad Tarhini;Emilie Routier;Olivier Lambotte

  • Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

    S. Champiat;S. Champiat;O. Lambotte;E. Barreau;R. Belkhir

  • Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.

    Aymeric Silvin;Nicolas Chapuis;Garett Dunsmore;Anne-Gaëlle Goubet

  • Cancer vaccines: the next immunotherapy frontier

    Unknown

  • Mechanisms and therapeutic implications of hypermutation in gliomas.

    Mehdi Touat;Mehdi Touat;Mehdi Touat;Yvonne Y. Li;Yvonne Y. Li;Adam N. Boynton;Adam N. Boynton;Liam F. Spurr;Liam F. Spurr

  • Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

    Eleonora De Martin;Jean-Marie Michot;Barbara Papouin;Stéphane Champiat

  • Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

    Lucile Vanhersecke;Maxime Brunet;Jean-Philippe Guégan;Christophe Rey

  • Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

    Unknown

  • Intratumoural administration and tumour tissue targeting of cancer immunotherapies

    Ignacio Melero;Eduardo Castanon;Maite Alvarez;Stephane Champiat;Stephane Champiat;Stephane Champiat

  • Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

    Aurélien Marabelle;Holbrook Kohrt;Idit Sagiv-Barfi;Bahareh Ajami

  • Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

    Unknown

  • Hyperprogressive disease: recognizing a novel pattern to improve patient management

    Stéphane Champiat;Roberto Ferrara;Christophe Massard;Benjamin Besse

  • Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.

    Jean-Marie Michot;Laurence Albiges;Nathalie Chaput;Veronique Saada

  • Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

    Audrey Simonaggio;Jean Marie Michot;Anne Laure Voisin;Jérome Le Pavec

  • Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

    Holbrook E. Kohrt;Ariane Thielens;Aurelien Marabelle;Aurelien Marabelle;Idit Sagiv-Barfi

  • Rationale for anti-OX40 cancer immunotherapy

    Sandrine Aspeslagh;Sophie Postel-Vinay;Sylvie Rusakiewicz;Jean-Charles Soria

  • Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

    M. Tazdait;L. Mezquita;J. Lahmar;R. Ferrara

Frequent Co-Authors

Laurence Zitvogel
Laurence Zitvogel University of Paris-Saclay
Caroline Robert
Caroline Robert University of Paris-Saclay
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Olivier Lambotte
Olivier Lambotte University of Paris-Saclay
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Guido Kroemer
Guido Kroemer Université Paris Cité
Ronald Levy
Ronald Levy Stanford University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Laurence Albiges
Laurence Albiges Institut Gustave Roussy
David Planchard
David Planchard Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, pursuing related online degrees can broaden career opportunities in healthcare and research. Many students consider advanced nursing programs to complement their immunology expertise. For example, an acute care NP certification can open doors to specialized patient care roles, particularly in critical and urgent care settings.

If you’re interested in accelerating your nursing career, exploring a nurse practitioner accelerated program could be a practical step. These programs typically offer pathways to become a nurse practitioner more quickly, integrating clinical knowledge that complements immunology studies well.

For those without a nursing background, enrolling in online RN programs for non nurses is an accessible way to enter the nursing profession. Many of these programs are designed with flexibility for working adults and offer strong foundations relevant to immunological care and research.

Finally, students looking for less competitive entry points might explore the easiest accelerated nursing programs to get into. Such programs provide faster, more attainable routes into nursing, supporting diverse immunology-related career pathways in healthcare.

Best Scientists Citing Aurélien Marabelle

Trending Scientists

Recently Published Articles